Insulin-Like Growth Factor-I Might be a Predictor for Severe Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients

Abstract

The aim of the study was to compare the IGF-1 levels, metabolic and clinical parameters among the ultrasonographically classified non-alcoholic fatty liver disease (NAFLD) groups and determine the factors that may predict the NAFLD severity in patients with morbid obesity. This study was conducted on 316 morbidly obese patients (250 F/66 M). The data of patients before and 1st-year after bariatric surgery were recorded. According to the ultrasonographically NAFLD screening, patients with normal hepatic features were classified as Group 1(n=57), with mild and moderate NAFLD were classified as Group 2(n=219), and with severe NAFLD were classified as Group 3(n=40). IGF-1 standard deviation scores (SDSIGF1) were calculated according to age and gender. Parameters that could predict the presence and severity of NAFLD were evaluated. IGF-1 levels were significantly associated with Group 3 than Group 1(p=0.037), and the significance remained between the same groups when IGF-1 levels were standardized as SDSIGF1(p=0.036). Decreased levels of SDSIGF1 explained 5% of severe NAFLD than the normal group (p=0.036). Liver Diameter, FPG, ALT, AST, and GGT were also found as significant predictors for severe NAFLD. There were significant differences between pre-and postop values in all groups (p<0.001). This study showed that IGF-1 might be considered a sgnificant predictor of severe NAFLD in morbidly obese patients. It is crucial in clinical practice to determine predictive factors of NAFLD that could support the diagnosis accompanied by non-invasive imaging methods.

Publikationsverlauf

Eingereicht: 26. April 2022

Angenommen nach Revision: 19. Mai 2022

Accepted Manuscript online:
19. Mai 2022

Artikel online veröffentlicht:
15. Juli 2022

• References

• 1 Collaboration NCDRF. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017; 390: 2627-2642
• 2 Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 2019; 15: 288-298
• 3 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
• 4 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: clinical and experimental 2016; 65: 1038-1048
• 5 Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-2273
• 6 Zelber-Sagi S, Lotan R, Shlomai A. et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56: 1145-1151
• 7 Galli G, Pinchera A, Piaggi P. et al. Serum insulin-like growth factor-1 concentrations are reduced in severely obese women and raise after weight loss induced by laparoscopic adjustable gastric banding. Obes Surg 2012; 22: 1276-1280
• 8 Fusco A, Miele L, D’Uonnolo A. et al. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol 2012; 77: 531-536
• 9 Arturi F, Succurro E, Procopio C. et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 2011; 96: E1640-E1644
• 10 Sandhu MS, Heald AH, Gibson JM. et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 1740-1745
• 11 Garcia-Galiano D, Sanchez-Garrido MA, Espejo I. et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007; 17: 493-503
• 12 Amin A, Siddiq G, Haider MI. et al. Laparoscopic sleeve gastrectomy versus lifestyle modification in class I obesity in Pakistani population: a prospective cohort study. Cureus 2019; 11: e5031
• 13 Schmitz SM, Kroh A, Koch A. et al. Comparison of liver recovery after Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass. Obes Surg 2021; 31: 3218-3226
• 14 Statistics NCfH. Third national health and nutrition examination survey: hepatic steatosis ultrasound images assessment procedures manual accessed May 29, 2018 www.cdc.gov
• 15 Takeuchi Y, Ito H, Komatsu Y. et al. Non-alcoholic fatty liver disease is an independent predictor for macroangiopathy in Japanese type 2 diabetic patients: a cross-sectional study. Intern Med 2012; 51: 1667-1675
• 16 [Anonymous] Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res 1998; 6 (Suppl. 02) 51S-209S
• 17 Isojima T, Shimatsu A, Yokoya S. et al. Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 2012; 59: 771-780
• 18 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 19 Mallea-Gil MS, Ballarino MC, Spiraquis A. et al. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol Latinoam 2012; 42: 20-26
• 20 Hagstrom H, Stal P, Hultcrantz R. et al. IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study. Scandinavian journal of gastroenterology 2017; 52: 1427-1434
• 21 Chishima S, Kogiso T, Matsushita N. et al. The relationship between the growth hormone/insulin-like growth factor system and the histological features of nonalcoholic fatty liver disease. Intern Med 2017; 56: 473-480
• 22 Colak Y, Senates E, Ozturk O. et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 2012; 24: 255-261
• 23 Marques V, Afonso MB, Bierig N. et al. Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD. Front Med 2021; 8: 683250
• 24 Sirbu A, Gologan S, Arbanas T. et al. Adiponectin, body mass index and hepatic steatosis are independently associated with IGF-I status in obese non-diabetic women. Growth Horm IGF Res 2013; 23: 2-7
• 25 Sumida Y, Yonei Y, Tanaka S. et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res 2015; 45: 771-781
• 26 Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci 2018; 19
• 27 Friedrich N, Thuesen B, Jorgensen T. et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35: 768-773
• 28 Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disorders 2004; 28: 167-172
• 29 Atsawarungruangkit A, Chenbhanich J, Dickstein G. C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population. World J Gastroenterol 2018; 24: 3663-3670
• 30 Hasaneen M, Yousef M, Elamin A. et al. Characterization of liver changes in obese patient using computed tomography. Eur Acad Res 2019; VI 5625-5635
• 31 Salomone F, Sharaiha RZ, Boskoski I. Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives. Liver Int 2020; 40: 1262-1268